Dual Inhibition of the Endothelin and Angiotensin Receptor Ameliorates Renal and Inner Ear Pathologies in Alport Mice
Efficacy and Safety of ACE Inhibitor and Angiotensin Receptor Blocker Therapies in Primary Focal Segmental Glomerulosclerosis Treatment: A Systematic Review and Meta-Analysis
Differentiating Primary and Secondary FSGS Using Non-Invasive Urine Biomarkers
Sparsentan Clinical Trials in Glomerular Diseases: Defining Endpoints and a Path Forward in Light of the Parasol Initiative
The Dual Endothelin A and Angiotensin II Type 1 Receptor Antagonist Sparsentan (FILSPARI®) Exhibits a Safe Nonclinical Male Fertility Toxicity Profile
Mechanism of Protective Actions of Sparsentan in the Kidney: Lessons From Studies in Models of Chronic Kidney Disease
Sparsentan: The First and Only Non-Immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy
Sparsentan, a Dual Endothelin Type A and Angiotensin II Subtype 1 Receptor Antagonist for the Treatment of Immunoglobulin A Nephropathy: Latest Trial Results, Pharmacokinetic Considerations, and Binding Profile
Society for Inherited Metabolic Disorders (SIMD) Annual Meeting 2024
April 14 - 17, 2024
Charlotte
Association Between Homocysteine and Clinical Outcomes in Patients With Classical Homocystinuria: A Systematic Literature Review
Matching-Adjusted Indirect Comparisons of eGFR Slopes in the PROTECT study with UK RaDaR IgA Nephropathy Population and the Control Arm of NefIgArd
Practical Considerations for the Use of Sparsentan in the Treatment of Patients with IgAN in Clinical Practice
Humanistic and Economic Burden of IgA Nephropathy: Systematic Literature Reviews and Narrative Synthesis